Search research articles
Contact Us
Filters
Showing results (1-10 of 155) with videos related to
Page
of 16
Sort By:
Journal of Dermatological Science
|
November 5, 2002
Neuromediators--a crucial component of the skin immune system
Thomas A Luger
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 22, 2016
VORWORT
Thomas A Luger
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 17, 2005
[Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)]
Thomas A Luger, Harald Gollnick
Journal of the American Academy of Dermatology
|
April 17, 2007
Lichen planus responding to efalizumab
Markus Böhm, Thomas A Luger
Current Opinion in Investigational Drugs (London, England : 2000)
|
July 2, 2002
Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases
Anita Rütter, Thomas A Luger
Experimental Dermatology
|
October 28, 2004
Melanocortins in fibroblast biology--current update and future perspective for dermatology
Markus Böhm, Thomas A Luger
Clinical and Experimental Rheumatology
|
October 17, 2015
The skin in psoriasis: assessment and challenges
Vinzenz Oji, Thomas A Luger
Handbook of Experimental Pharmacology
|
April 12, 2015
NK-1 Antagonists and Itch
Sonja Ständer, Thomas A Luger
The Journal of Investigative Dermatology
|
March 19, 2015
An α-MSH analog in erythropoietic protoporphyria
Thomas A Luger, Markus Böhm
American Journal of Clinical Dermatology
|
June 10, 2004
Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view
Anita Ruetter, Thomas A Luger
Page
of 16
Search research articles
Search
Showing results (1-10 of 155) with videos related to
Sort By:
Page
of 16
Journal of Dermatological Science
|
November 5, 2002
Neuromediators--a crucial component of the skin immune system
Thomas A Luger
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 22, 2016
VORWORT
Thomas A Luger
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
May 17, 2005
[Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)]
Thomas A Luger, Harald Gollnick
Journal of the American Academy of Dermatology
|
April 17, 2007
Lichen planus responding to efalizumab
Markus Böhm, Thomas A Luger
Current Opinion in Investigational Drugs (London, England : 2000)
|
July 2, 2002
Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases
Anita Rütter, Thomas A Luger
Experimental Dermatology
|
October 28, 2004
Melanocortins in fibroblast biology--current update and future perspective for dermatology
Markus Böhm, Thomas A Luger
Clinical and Experimental Rheumatology
|
October 17, 2015
The skin in psoriasis: assessment and challenges
Vinzenz Oji, Thomas A Luger
Handbook of Experimental Pharmacology
|
April 12, 2015
NK-1 Antagonists and Itch
Sonja Ständer, Thomas A Luger
The Journal of Investigative Dermatology
|
March 19, 2015
An α-MSH analog in erythropoietic protoporphyria
Thomas A Luger, Markus Böhm
American Journal of Clinical Dermatology
|
June 10, 2004
Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view
Anita Ruetter, Thomas A Luger
Page
of 16